Gramigut

Gramigut is an ophthalmic preparation containing the fluoroquinolone antibiotic ofloxacin; the specific strength and dosage form are not disclosed, but it is supplied as a prescription‑only ocular product marketed in the European Union. It is intended for the treatment of bacterial infections of the eye and is classified under ATC code S01EA02. Physicians prescribe Gramigut based on clinical assessment of ocular bacterial conditions and local antimicrobial susceptibility.

Gramigut is indicated for the management of bacterial infections affecting the eye, where the causative organisms are known or suspected to be susceptible to ofloxacin. - Bacterial conjunctivitis caused by susceptible organisms. - Keratitis (inflammation of the cornea) due to bacterial pathogens. - Blepharitis with confirmed bacterial etiology. - Post‑operative ocular infections following cataract or refractive surgery. - Other ocular bacterial infections as determined by a healthcare professional. - Acute bacterial iritis responsive to fluoroquinolone therapy.

Adverse reactions reported with Gramigut are generally related to the ocular surface and vary in frequency.

Common: - Transient eye irritation or burning sensation. - Redness of the conjunctiva. - Mild itching or foreign‑body sensation. - Temporary blurred vision. - Mild eyelid edema. - Dry eye sensation. - Photophobia.

Serious: - Corneal ulceration or perforation. - Severe allergic reaction with swelling of the eyelids and conjunctiva. - Vision loss due to optic nerve involvement (rare). - Persistent intraocular inflammation. - Development of resistant bacterial strains (clinical concern).

Before prescribing Gramigut, clinicians should evaluate patient history and ocular condition to minimize risk. - Avoid use in patients with known hypersensitivity to ofloxacin or other fluoroquinolones. - Use with caution in individuals with a history of tendon disorders, although ocular exposure is low. - Do not apply to eyes with viral or fungal infections without appropriate antimicrobial coverage. - Monitor patients with pre‑existing corneal disease for delayed healing. - Limit duration of therapy to the shortest effective period to reduce resistance. - Pregnant or nursing women should be assessed by a physician, as safety data are limited.

Ofloxacin can interact with other ophthalmic or systemic agents; awareness of these interactions helps ensure safe use of Gramigut.

Avoid: - Concurrent use of topical ophthalmic corticosteroids without antimicrobial coverage, which may mask infection. - Co‑administration with other fluoroquinolone eye drops, increasing risk of toxicity.

Use with caution: - Systemic fluoroquinolones, as additive effects on tendon or cartilage may be theoretical. - Anticholinergic eye drops that may affect pupil size and ocular comfort. - NSAID eye drops, which could increase risk of corneal complications.